PRMT5 inhibitor GSK3326595, currently in phase I clinical trial for solid tumors and non-Hodgkin’s lymphoma (NCT02783300; ClinicalTrials.gov), acts by occupying the binding site of substrate peptides in the PRMT5/MEP50 complex and thereby inhibits the enzymatic activity of PRMT5. Here, WDR77 is linked to non-Hodgkin lymphoma.